Discovery Lab pulmonary news

DSCO hired Jefferies & Co. to help the company seek strategic alternatives, including potential business alliances, commercial and development partnerships, financings, business combinations and other similar opportunities. The move follows several delays for the company's Surfaxin lucinactant to prevent and treat respiratory distress syndrome (RDS) in premature infants. Earlier this month, DSCO withdrew an MAA for the product because of previously announced manufacturing problems (see BioCentury, June 12). In April, the company said that the problems would delay U.S. approval of the synthetic lung surfactant until late 2007. ...